GlobalData on MSN1d
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...
Business Wire3d
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...
Fintel on MSN2d
HC Wainwright & Co. Upgrades NovoCure (NVCR)
Fintel reports that on October 16, 2024, HC Wainwright & Co. upgraded their outlook for NovoCure (NasdaqGS:NVCR) from Neutral ...
The Pharma Letter2d
FDA approves Novocure’s Optune Lua
The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or ...
STAT2d
A controversial approval for Novocure’s device
The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.
Morningstar3d
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
“Novocure is committed to extending ... cancer-related death worldwide1, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. It is estimated that ...
kalkinemedia2d
A 10.7% Surge Recorded for NovoCure (NVCR); Future Gains Speculated
Highlights:,Significant Stock Surge:,NovoCure's shares rose by 10.7% to $17.78, driven by substantial trading volume following FDA approval of its Optune Lua device for metastatic non-small cell lung ...
Investing3d
FDA approves new NSCLC treatment Optune Lua
Lung cancer remains the leading cause of cancer-related death worldwide, with NSCLC accounting for approximately 85% of all ... Novocure. The FDA approval of Optune Lua for metastatic non-small ...